

3012
1103326-0282
33
PB
5/9/03**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants : Cederberg et al.
Serial No. : 08/945,425
Filed : October 21, 1997
For : ADMINISTRATION OF
PHARMACEUTICALS
Examiner : Desai, R.
Group Art Unit : 1612

FAX RECEIVED

MAY 08 2003

GROUP 1600

OFFICIAL

CERTIFICATE OF TRANSMISSION UNDER 37 C.F.R. 1.8

I hereby certify that this paper is being
facsimile transmitted to the U.S. Patent and
Trademark Office on the date indicated below
at the facsimile number 703-308-4556.

Andrew Fessak 48,528
Agent Name PTO Reg. No.

Andrew Fessak 5/7/03
Signature Date of Signature

Assistant Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

ATTENTION: Examiner R. Desai
FACSIMILE NO: 703-308-4556
DATE: May 7, 2003
PAGES: 5 pages

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.97(c)**

Sir:

Applicants submit this communication and the attached Form PTC-1449 in compliance
with 37 C.F.R. §§1.56, 1.97 and 1.98. A copy of the document listed on the Form PTO-1449 is
enclosed as part of this communication.

Serial No. 08/945,425, filed Oct. 21, 1997

Docket No. 1103326-0282

Page 2 of 3

The document listed on Form PTO-1449, CN 1080168, was first cited in an Office Action from the Chinese Patent Office during the examination of the Chinese member of the same patent family as the instant application. The Chinese Office Action was issued not more than 3 months from the filing date of this Information Disclosure Statement.

As part of this communication, Applicants are providing an English-language abstract of CN 1080168 listed on Form PTO-1449.

Consideration of the document listed on Form PTO-1449 is respectfully requested.

TIME OF TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

This Information Disclosure Statement is being filed after the period specified in 37 C.F.R. §1.97(b) but before the mailing date of either:

- (1) a final action under §1.113 or
- (2) a notice of allowance under §1.311,

whichever occurs first.

STATEMENT OR FEE

Accompanying this Information Disclosure Statement is

- A. ☒ a statement as specified in 37 C.F.R. §1.97 (e)(1).

OR

- B. ☐ the fee set forth in 37 C.F.R. §1.17(p) for submission of an information disclosure statement under §1.97(c). (\$180.00).

Serial No. 08/945,425, filed Oct. 21, 1997

Docket No. 1103326-0282

Page 3 of 3

STATEMENT UNDER 37 C.F.R. § 1.97(e)(1)

I hereby state that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

No fee should be due in connection with this communication. If any fee is due, the Assistant Commissioner is authorized to charge the fee to Deposit Account No. 23-1703.

Dated: May 7, 2003

Respectfully submitted,

Andrew Fessak

Andrew Fessak

Reg. No. 48,528

Agent for Applicant

Customer No. 00747C

White & Case LLP

Agent's Direct Dial: (212) 819-8437